- Home
- NVCT vs DHY Comparison
NVCT vs DHY Comparison
Compare NVCT & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | DHY |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 208.3M |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | NVCT | DHY |
|---|---|---|
| Price | $8.99 | $1.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.33 | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 567.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $1.82 |
| 52 Week High | $11.52 | $2.16 |
Technical Indicators
Market Signals| Indicator | NVCT | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 23.17 |
| Support Level | $8.01 | N/A |
| Resistance Level | $9.20 | $2.14 |
| Average True Range (ATR) | 0.42 | 0.03 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 54.76 | 7.41 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.